Pain Pointers
Early intervention and careful management are critical in the treatment of peripheral neuropathy
Peripheral neuropathy is a common occurrence in patients with hematologic diseases, whether from the disease itself or the chemotherapy used to treat...
Online Exclusives
JAMA Editor-in-Chief Resigns After Releasing Content Questioning Racism in Medicine
In late June, Howard Bauchner, MD, will resign from his role as editor-in-chief of the Journal of the American Medical Association (JAMA) following a...
Will DIY Testing Outlive the COVID-19 Pandemic?
The COVID-19 pandemic has revolutionized diagnostic testing. As the pandemic eases and related restrictions are lifted, public health officials and scientists are looking to...
News
From the Blood Journals
Does Rheumatic Disease Increase Risk of MGUS Progression to Hematologic Malignancies?
Patients with monoclonal gammopathy of undetermined significance (MGUS) and concomitant non-antibody (Ab)–mediated inflammatory rheumatic diseases are at increased risk of progression to overt multiple...
More COVID-19 Complications Seen in Black Patients With Sickle Cell Disease...
Patients with sickle cell disease (SCD) and sickle cell trait (SCT) have significantly higher rates of hospitalization, pneumonia, and pain related to COVID-19 compared...
Multimedia
Vincent Wagner and Ellen Marcus: Use of the Khorana Score to...
Vincent Wagner, MD, and Ellen Marcus, BA, discuss the Khorana score's role in assessing risk of venous thromboembolism (VTE) in patients with gynecological cancers.
Curtis Andrew Lachowiez: Ivosidenib + Venetoclax and Azacitidine in IDH-Mutated Myeloid...
In this video, Curtis Andrew Lachowiez, MD, discusses interim results from a small study of patients with IDH1-mutated myeloid malignancies who were treated with ivosidenib plus...
Kathi Mooney: Impact of Remote Monitoring on Patients with Cancer During...
Remote monitoring and treatment of cancer and treatment-related symptoms during the COVID-19 pandemic was associated with significant reductions in symptom burden and improvements in...
Paolo Ghia: Ibrutinib Plus Venetoclax Produces Deep Responses in Patients with...
Here, Paolo Ghia, MD, PhD, of Vita-Salute San Raffaele University in Milan, Italy, discusses recent findings from the phase II CAPTIVATE study evaluating fixed-duration...
On Location
Rusfertide Helps Patients With Polycythemia Vera Avoid Phlebotomy
Patients with polycythemia vera (PV) who received rusfertide were able to avoid therapeutic phlebotomy for...
Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML
In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association,...
Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL
For patients with chronic lymphocytic leukemia (CLL) who are considered unfit for FCR chemotherapy (fludarabine,...
R-CHOP Versus R-EPOCH: No Difference in Survival for Patients With MYC-Rearranged, Double- or Triple-Hit DLBCL
Overall survival (OS) outcomes were similar between patients with MYC-rearranged diffuse large B-cell lymphoma (DLBCL)...
Investigators Identify Distinct Molecular Subgroups to Guide Treatment Decisions in AML
Analyzing genetic data from more than 3,000 patients with acute myeloid leukemia (AML), researchers from...
Evaluating Enasidenib, With or Without Azacitidine, in Patients with IDH2-Mutated MDS
Enasidenib was had a tolerable safety profile and showed promising clinical activity in patients with...
Latest Headlines
ASH Directions
ASH Minority Recruitment Initiative Seeks Mentors, ASH Joins in Support of the Federal Safe...
Mentors Needed for ASH Minority Recruitment Initiative
The American Society of Hematology (ASH) Minority Recruitment Initiative (MRI), which was created nearly two decades ago to...
ASH Presents FAQ Resource for Thrombosis with Thrombocytopenia, ASH News Daily Seeks 2021 Authors,...
New COVID-19 Resource: FAQ About Thrombosis with Thrombocytopenia Syndrome
The American Society of Hematology (ASH) has released a resource to guide clinicians in recognizing and...
Remembering Thomas Brock, Xavier Becerra Confirmed as U.S. Health Secretary, and more
Remembering Thomas Brock (1926 - 2021)
Thomas Brock, PhD, died on April 4, 2021 at the age of 94. Dr. Brock’s discovery of a species...
Senate Confirms Surgeon General and Assistant Secretary for Health, HVO Presents Golden Apple Awards,...
Brian Bolwell Named Chair of Physician Leadership and Development at Cleveland Clinic
The Cleveland Clinic has appointed Brian Bolwell, MD, FACP, as chair of physician...
Remembering Emil Freireich, Millie Hughes-Fulford, and more
Remembering Emil Freireich (1927 – 2021)
Renowned hematologist and researcher Emil Freireich, MD, died on February 1, 2021, at the age of 93.Dr. Freireich had...
Pain Pointers
Early intervention and careful management are critical in the treatment of peripheral neuropathy
Peripheral neuropathy is a common occurrence in patients with hematologic diseases, whether...
Gene Therapy: The Comeback Kid of Hematology Treatments?
Despite slow progress and unexpected setbacks, the future of gene therapy remains bright.
Ashanthi de Silva was the first human to be treated successfully with...
Four of a Kind?
Soon, there may be as many as four JAK inhibitors available for patients with myelofibrosis.
For many of his patients with myelofibrosis, ruxolitinib has been...